Temasek Holdings Private Ltd Sells 51,119 Shares of Eli Lilly and Company $LLY

Temasek Holdings Private Ltd trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 30.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 117,847 shares of the company’s stock after selling 51,119 shares during the period. Temasek Holdings Private Ltd’s holdings in Eli Lilly and Company were worth $126,648,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Rakuten Investment Management Inc. boosted its position in Eli Lilly and Company by 248.2% in the 4th quarter. Rakuten Investment Management Inc. now owns 104,905 shares of the company’s stock valued at $113,164,000 after buying an additional 74,779 shares during the period. Codex Capital Asset Management L.L.C. boosted its position in Eli Lilly and Company by 8.1% in the 4th quarter. Codex Capital Asset Management L.L.C. now owns 18,380 shares of the company’s stock valued at $19,753,000 after buying an additional 1,380 shares during the period. Beacon Financial Advisory LLC boosted its position in Eli Lilly and Company by 34.8% in the 4th quarter. Beacon Financial Advisory LLC now owns 639 shares of the company’s stock valued at $687,000 after buying an additional 165 shares during the period. Abound Financial LLC purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $161,000. Finally, Bluedoor Private Wealth LLC purchased a new stake in Eli Lilly and Company in the 4th quarter valued at about $1,507,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it is acquiring 4E Therapeutics, a developer of non-opioid pain treatments, expanding beyond obesity and diabetes into the large painkiller market. Investors may view the deal as a strategic move to diversify Lilly’s pipeline and create another long-term growth driver. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also advanced several early-stage programs, including an oral candidate, an Alzheimer’s drug, and other clinical trial updates, which suggests Lilly continues to deepen its pipeline beyond its blockbuster GLP-1 franchise. Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study
• Positive Sentiment: Broader sector and market commentary remains constructive for GLP-1 leaders like Lilly, with reports projecting strong long-term growth in the global GLP-1 receptor agonist market. Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035
• Neutral Sentiment: Healthcare stocks were broadly firmer in afternoon trading, which may be providing a small tailwind for Lilly alongside the company-specific news. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Negative Sentiment: Some headlines point to competitive pressure from Novo Nordisk and concerns that Lilly’s GLP-1 drugs could face new reimbursement or demand headwinds, which could temper enthusiasm if those risks grow. Eli Lilly’s hottest drugs face a quiet new threat

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,122.47 on Wednesday. The company has a 50 day moving average price of $1,006.08 and a 200-day moving average price of $1,016.63. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,182.73. The stock has a market capitalization of $1.06 trillion, a PE ratio of 39.87, a PEG ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the company earned $3.34 EPS. The company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on LLY shares. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Leerink Partners set a $1,119.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 26th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.